M. Allende

Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression.

T. Walsh, P. Pizzo, J. Berenguer, 1995, American journal of respiratory and critical care medicine.

Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis

T. Walsh, P. Pizzo, J. Berenguer, 1994, Antimicrobial Agents and Chemotherapy.

Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma

S. Piscitelli, T. Walsh, P. Pizzo, 1994, Antimicrobial Agents and Chemotherapy.

Reticuloendothelial loading with amphotericin b lipid complex ablc a novel pharmacodynamic approach to treatment of experimental hepatosplenic candidiasis hsc

A. Francesconi, J. Lee, C. Lyman, 1992 .

Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy

A. Francesconi, T. Walsh, P. Pizzo, 1995, Antimicrobial agents and chemotherapy.

Pulmonary cryptococcosis presenting as metastases in children with sarcomas.

M. Horowitz, T. Walsh, P. Pizzo, 1993, The Pediatric infectious disease journal.

Immune-based Therapies for HIV Infection

H. Lane, M. Allende, 2004 .

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

R. Davey, H. Lane, H. Salomón, 2000, The Journal of infectious diseases.

CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.

R. Davey, H. Lane, K. Ruxrungtham, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Increasing CD4+ T cells specific for tuberculosis correlate with improved clinical immunity after highly active antiretroviral therapy.

R. Dewar, J. Metcalf, H. Lane, 2002, AIDS research and human retroviruses.